التفاصيل البيبلوغرافية
| العنوان: |
Facile synthesis of multi-faceted, biomimetic and cross-protective nanoparticle-based vaccines for drug-resistant Shigella: a flexible platform technology |
| المؤلفون: |
Baruah, Namrata, Ahamad, Nadim, Halder, Prolay, Koley, Hemanta, Katti, Dhirendra S. |
| المساهمون: |
Department of Biotechnology, Ministry of Science and Technology, India, Council of Scientific and Industrial Research, India, Indian Council of Medical Research |
| المصدر: |
Journal of Nanobiotechnology ; volume 21, issue 1 ; ISSN 1477-3155 |
| بيانات النشر: |
Springer Science and Business Media LLC |
| سنة النشر: |
2023 |
| مصطلحات موضوعية: |
Pharmaceutical Science, Applied Microbiology and Biotechnology, Biomedical Engineering, Molecular Medicine, Medicine (miscellaneous), Bioengineering |
| الوصف: |
Background No commercial vaccines are available against drug-resistant Shigella due to serotype-specific/narrow-range of protection. Nanoparticle-based biomimetic vaccines involving stable, conserved, immunogenic proteins fabricated using facile chemistries can help formulate a translatable cross-protective Shigella vaccine. Such systems can also negate cold-chain transportation/storage thus overcoming challenges prevalent in various settings. Methods We explored facile development of biomimetic poly (lactide- co -glycolide)/PLGA 50:50 based nanovaccines (NVs), encapsulating conserved stabilized antigen(s)/immunostimulant of S. dysenteriae 1 origin surface-modified using simple chemistries. All encapsulants (IpaC/IpaB/LPS) and nanoparticles (NPs)—bare and modified (NV), were thoroughly characterized. Effect of IpaC on cellular uptake of NPs was assessed in-vitro. Immunogenicity of the NVs was assessed in-vivo in BALB/c mice by intranasal immunization. Cross-protective efficacy was assessed by intraperitoneally challenging the immunized groups with a high dose of heterologous S. flexneri 2a and observing for visible diarrhea, weight loss and survival. Passive-protective ability of the simplest NV was assessed in the 5-day old progeny of vaccinated mice. Results All the antigens and immunostimulant to be encapsulated were successfully purified and found to be stable both before and after encapsulation into NPs. The ~ 300 nm sized NPs with a zeta potential of ~ − 25 mV released ~ 60% antigen by 14th day suggesting an appropriate delivery kinetics. The NPs could be successfully surface-modified with IpaC and/or CpG DNA. In vitro experiments revealed that the presence of IpaC can significantly increase cellular uptake of NPs. All NVs were found to be cytocompatible and highly immunogenic. Antibodies in sera of NV-immunized mice could recognize heterologous Shigella . Immunized sera also showed high antibody and cytokine response. The immunized groups were protected from diarrhea and weight loss with ~ 70–80% ... |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1186/s12951-023-01780-y |
| DOI: |
10.1186/s12951-023-01780-y.pdf |
| DOI: |
10.1186/s12951-023-01780-y/fulltext.html |
| الإتاحة: |
https://doi.org/10.1186/s12951-023-01780-yTest |
| حقوق: |
https://creativecommons.org/licenses/by/4.0Test ; https://creativecommons.org/licenses/by/4.0Test |
| رقم الانضمام: |
edsbas.9094C8F9 |
| قاعدة البيانات: |
BASE |
